Literature DB >> 20061547

Innate immunity mediates myocardial preconditioning through Toll-like receptor 2 and TIRAP-dependent signaling pathways.

Jian-Wen Dong1, Jesus G Vallejo, Huei-Ping Tzeng, James A Thomas, Douglas L Mann.   

Abstract

Recent studies have implicated Toll-like receptor 2 (TLR2) and TLR4 signaling in delimiting liver and brain injury following ischemia-reperfusion (I/R). To determine whether TLR2 and TLR4 conferred cytoprotection in the heart, we subjected hearts of wild-type (WT) mice and mice deficient in TLR2 (TLR2D), TLR4 (TLR4D), and TIR domain-containing adapter protein (TIRAP-D) to ischemic preconditioning (IPC). Langendorff-perfused hearts were subjected to 30 min ischemia and 60 min reperfusion with or without IPC. IPC resulted in a significant increase (P < 0.05) in the percent recovery of left ventricular developed pressure (%LVDP) in WT mouse hearts (54.4 +/- 2.7% of baseline), whereas there was no significant increase in %LVDP (P > 0.05) in TIRAP-D mouse hearts (43.8 +/- 1.9%) after I/R injury. IPC also resulted in a significant (P < 0.05) decrease in I/R-induced creatine kinase release and Evans blue dye uptake in WT but not TIRAP-D hearts. Interestingly, IPC resulted in a significant (P < 0.05) increase in %LVDP in TLR4-deficient hearts (52.7 +/- 3%) but not in TLR2D hearts (39.3 +/- 1.5%). Pretreatment with a specific TLR2 ligand (Pam3CSK) protected WT hearts against I/R-induced left ventricular dysfunction. The loss of IPC-induced cardioprotection in TIRAP-D mouse hearts was accompanied by a decreased translocation of protein kinase C-epsilon and decreased phosphorylation of GSK-3beta. Taken together, these data suggest that the cardioprotective effect of IPC is mediated, at least in part, through a TLR2-TIRAP-dependent pathway, suggesting that the modulation of this pathway represents a viable target for reducing I/R injury.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20061547      PMCID: PMC2838552          DOI: 10.1152/ajpheart.00306.2009

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  39 in total

1.  Tumor necrosis factor and viral myocarditis: the fine line between innate and inappropriate immune responses in the heart.

Authors:  D L Mann
Journal:  Circulation       Date:  2001-02-06       Impact factor: 29.690

2.  Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components.

Authors:  O Takeuchi; K Hoshino; T Kawai; H Sanjo; H Takada; T Ogawa; K Takeda; S Akira
Journal:  Immunity       Date:  1999-10       Impact factor: 31.745

3.  Seeing death in the living.

Authors:  R A Gottlieb; R N Kitsis
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

4.  The extra domain A of fibronectin activates Toll-like receptor 4.

Authors:  Y Okamura; M Watari; E S Jerud; D W Young; S T Ishizaka; J Rose; J C Chow; J F Strauss
Journal:  J Biol Chem       Date:  2001-01-09       Impact factor: 5.157

5.  HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine.

Authors:  A Asea; S K Kraeft; E A Kurt-Jones; M A Stevenson; L B Chen; R W Finberg; G C Koo; S K Calderwood
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

6.  TIRAP: an adapter molecule in the Toll signaling pathway.

Authors:  T Horng; G M Barton; R Medzhitov
Journal:  Nat Immunol       Date:  2001-09       Impact factor: 25.606

7.  Role of TLR-2 in the activation of nuclear factor kappaB by oxidative stress in cardiac myocytes.

Authors:  S Frantz; R A Kelly; T Bourcier
Journal:  J Biol Chem       Date:  2000-11-16       Impact factor: 5.157

8.  Evans Blue Dye as an in vivo marker of myofibre damage: optimising parameters for detecting initial myofibre membrane permeability.

Authors:  P W Hamer; J M McGeachie; M J Davies; M D Grounds
Journal:  J Anat       Date:  2002-01       Impact factor: 2.610

9.  The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors.

Authors:  Tiffany Horng; Gregory M Barton; Richard A Flavell; Ruslan Medzhitov
Journal:  Nature       Date:  2002-11-21       Impact factor: 49.962

Review 10.  Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart.

Authors:  Wei Chao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-11-14       Impact factor: 4.733

View more
  20 in total

1.  Toll-like receptor 4 signaling confers cardiac protection against ischemic injury via inducible nitric oxide synthase- and soluble guanylate cyclase-dependent mechanisms.

Authors:  E Wang; Yan Feng; Ming Zhang; Lin Zou; Yan Li; Emmanuel S Buys; Peigen Huang; Peter Brouckaert; Wei Chao
Journal:  Anesthesiology       Date:  2011-03       Impact factor: 7.892

Review 2.  Therapeutic targeting of innate immunity in the failing heart.

Authors:  Veli K Topkara; Sarah Evans; Weili Zhang; Slava Epelman; Lora Staloch; Philip M Barger; Douglas L Mann
Journal:  J Mol Cell Cardiol       Date:  2010-11-10       Impact factor: 5.000

Review 3.  Toll-like receptors: new players in myocardial ischemia/reperfusion injury.

Authors:  Tuanzhu Ha; Li Liu; Jim Kelley; Race Kao; David Williams; Chuanfu Li
Journal:  Antioxid Redox Signal       Date:  2011-04-08       Impact factor: 8.401

Review 4.  Innate immunity as a target for acute cardioprotection.

Authors:  Coert J Zuurbier; Antonio Abbate; Hector A Cabrera-Fuentes; Michael V Cohen; Massimo Collino; Dominique P V De Kleijn; James M Downey; Pasquale Pagliaro; Klaus T Preissner; Masafumi Takahashi; Sean M Davidson
Journal:  Cardiovasc Res       Date:  2019-06-01       Impact factor: 10.787

5.  TLR2 ligands induce cardioprotection against ischaemia/reperfusion injury through a PI3K/Akt-dependent mechanism.

Authors:  Tuanzhu Ha; Yulong Hu; Li Liu; Chen Lu; Julie R McMullen; Jim Kelley; Race L Kao; David L Williams; Xiang Gao; Chuanfu Li
Journal:  Cardiovasc Res       Date:  2010-04-26       Impact factor: 10.787

Review 6.  The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls.

Authors:  Douglas L Mann
Journal:  Circ Res       Date:  2011-04-29       Impact factor: 17.367

Review 7.  TLR2 and TLR4 in ischemia reperfusion injury.

Authors:  F Arslan; B Keogh; P McGuirk; A E Parker
Journal:  Mediators Inflamm       Date:  2010-06-09       Impact factor: 4.711

Review 8.  The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis.

Authors:  Sumanth D Prabhu; Nikolaos G Frangogiannis
Journal:  Circ Res       Date:  2016-06-24       Impact factor: 17.367

9.  CpG-ODN, the TLR9 agonist, attenuates myocardial ischemia/reperfusion injury: involving activation of PI3K/Akt signaling.

Authors:  Zhijuan Cao; Danyang Ren; Tuanzhu Ha; Li Liu; Xiaohui Wang; John Kalbfleisch; Xiang Gao; Race Kao; David Williams; Chuanfu Li
Journal:  Biochim Biophys Acta       Date:  2012-08-16

Review 10.  Innate immune receptors in heart failure: Side effect or potential therapeutic target?

Authors:  Katharina B Wagner; Stephan B Felix; Alexander Riad
Journal:  World J Cardiol       Date:  2014-08-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.